

WEST Search History

DATE: Wednesday, November 13, 2002

Set Name Query
side by side

Hit Count Set Name
result set

*DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;
OP=ADJ*

L19	recombinant same relaxin and stroke?	0	L19
L18	recombinant adj relaxin and (ischemic same cardiac)	1	L18
L17	recombinant adj relaxin and (ischemic same wound)	1	L17
L16	recombinant adj relaxin and (pulmonary same hypertension)	1	L16
L15	recombinant adj relaxin and hypertension and (renal same function?)	0	L15
L14	recombinant adj relaxin and (vasodilation or vasodilator?)and hypertension	1	L14
L13	relaxin and stroke?	9	L13
L12	relaxin and (ischemic same cardiac)	10	L12
L11	relaxin and (ischemic same wound)	11	L11
L10	relaxin and (renal same hypertension)	13	L10
L9	relaxin and (pulmonary same hypertension)	8	L9
L8	relaxin and hypertension and (renal same function?)	3	L8
L7	relaxin and (vasodilation or vasodilator?)and hypertension and (renal same function?)	2	L7
L6	relaxin and (vasodilation or vasodilator?)and hypertension	17	L6
L5	relaxin and (vasodilation or vasodilator?)	47	L5
L4	5166191.pn.	2	L4
L3	08050745.ap.	0	L3
L2	unemori-elaine.in.	7	L2
L1	unemori-elaine-n\$.in.	1	L1

END OF SEARCH HISTORY

WEST

Search Results - Record(s) 1 through 9 of 9 returned.

1. Document ID: US 20020151681 A1

L13: Entry 1 of 9

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5

2. Document ID: US 20020114848 A1

L13: Entry 2 of 9

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020114848

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020114848 A1

TITLE: Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Woods, Gordon L.	Moscow	ID	US	

US-CL-CURRENT: 424/654; 514/171, 514/43

3. Document ID: US 20020039599 A1

L13: Entry 3 of 9

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039599

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020039599 A1

TITLE: Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

PUBLICATION-DATE: April 4, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lin, Henry C.	Manhattan Beach	CA	US	
Pimentel, Mark	Los Angeles	CA	US	

US-CL-CURRENT: 424/558; 514/2, 514/714[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 4. Document ID: US 5888764 A

L13: Entry 4 of 9

File: USPT

Mar 30, 1999

US-PAT-NO: 5888764

DOCUMENT-IDENTIFIER: US 5888764 A

TITLE: Human fas gene promoter region

DATE-ISSUED: March 30, 1999

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mountz; John D.	Birmingham	AL		
Liu; Changdan	Alabaster	AL		
Cheng; Jianhua	Alabaster	AL		
Koopman; William J.	Indian Springs	AL		
Zhou; Tong	W. Stonebrook Pl.	AL		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/455, 435/458, 435/471,
435/472, 435/476, 536/23.5, 536/23.51, 536/24.1, 536/24.31[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 5. Document ID: US 5811388 A

L13: Entry 5 of 9

File: USPT

Sep 22, 1998

US-PAT-NO: 5811388

DOCUMENT-IDENTIFIER: US 5811388 A

TITLE: Delivery of drugs to the lower GI tract

DATE-ISSUED: September 22, 1998

INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Friend; David R.	Menlo Park	CA		
Wong; David	San Francisco	CA		

US-CL-CURRENT: 514/2; 424/465, 424/474, 424/475, 424/479, 424/481, 424/485, 424/488, 424/85.1, 514/12, 514/177, 514/178, 514/179, 514/180, 514/181, 514/182, 514/21, 514/3, 514/777, 514/780, 514/782, 514/960, 514/961

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

6. Document ID: US 5378603 A

L13: Entry 6 of 9

File: USPT

Jan 3, 1995

US-PAT-NO: 5378603

DOCUMENT-IDENTIFIER: US 5378603 A

TITLE: Method and composition for identifying substances which activate transcription of the LDL receptor gene

DATE-ISSUED: January 3, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brown; Michael S.	Dallas	TX		
Goldstein; Joseph L.	Dallas	TX		
Russell; David W.	Dallas	TX		
Sudhof; Thomas C.	Dallas	TX		
Martin, Jr.; David W.	San Francisco	CA		

US-CL-CURRENT: 435/6; 435/29, 435/4, 436/817

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

7. Document ID: US 5256545 A

L13: Entry 7 of 9

File: USPT

Oct 26, 1993

US-PAT-NO: 5256545

DOCUMENT-IDENTIFIER: US 5256545 A

TITLE: Sterol Regulatory Elements

DATE-ISSUED: October 26, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brown; Michael S.	Dallas	TX		
Goldstein; Joseph L.	Dallas	TX		
Russell; David W.	Dallas	TX		
Sudhof; Thomas C.	Dallas	TX		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/358, 435/464, 435/465, 536/24.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

8. Document ID: US 5215910 A

L13: Entry 8 of 9

File: USPT

Jun 1, 1993

US-PAT-NO: 5215910

DOCUMENT-IDENTIFIER: US 5215910 A

TITLE: Host cells transformed with sterol regulatory elements

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brown; Michael S.	Dallas	TX		
Goldstein; Joseph L.	Dallas	TX		
Russell; David W.	Dallas	TX		
Sudhof; Thomas C.	Dallas	TX		

US-CL-CURRENT: 435/350; 435/320.1, 435/358, 435/363, 435/367, 435/370, 435/69.1,
536/24.1[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#) 9. Document ID: US 4935363 A

L13: Entry 9 of 9

File: USPT

Jun 19, 1990

US-PAT-NO: 4935363

DOCUMENT-IDENTIFIER: US 4935363 A

TITLE: Sterol regulatory elements

DATE-ISSUED: June 19, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brown; Michael S..	Dallas	TX		
Goldstein; Joseph L.	Dallas	TX		
Russell; David W.	Dallas	TX		
Sudhof; Thomas C.	Dallas	TX		

US-CL-CURRENT: 435/69.1; 435/207, 435/212, 435/226, 435/375, 435/41, 435/455,
435/69.4, 435/69.5, 435/69.51, 435/69.52, 536/23.2, 536/23.5, 536/23.51, 536/23.52[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
STROKE?	0
STROKEA.DWPI,TDBD,EPAB,USPT,PGPB.	2
STROKEB.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKED.DWPI,TDBD,EPAB,USPT,PGPB.	2774
STROKEE.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKEL.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKEN.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKER.DWPI,TDBD,EPAB,USPT,PGPB.	187
STROKES.DWPI,TDBD,EPAB,USPT,PGPB.	39254
(RELAXIN AND STROKE?).USPT,PGPB,EPAB,DWPI,TDBD.	9

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

[Previous Page](#) [Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 10 of 10 returned.

1. Document ID: US 20020122814 A1

L12: Entry 1 of 10

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/426; 424/718, 427/2.24[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

2. Document ID: US 20020022046 A1

L12: Entry 2 of 10

File: PGPB

Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/423[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#)

3. Document ID: US 20020019349 A1

L12: Entry 3 of 10

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)

[KMC](#) [Draw Desc](#) [Image](#)

4. Document ID: US 6479654 B1

L12: Entry 4 of 10

File: USPT

Nov 12, 2002

US-PAT-NO: 6479654

DOCUMENT-IDENTIFIER: US 6479654 B1

TITLE: Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baird; Andrew	San Diego	CA		
Andreason; Grai	La Jolla	CA		

US-CL-CURRENT: 536/23.5; 435/320.1, 536/23.1

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)

[KMC](#) [Draw Desc](#) [Image](#)

5. Document ID: US 6440726 B1

L12: Entry 5 of 10

File: USPT

Aug 27, 2002

US-PAT-NO: 6440726

DOCUMENT-IDENTIFIER: US 6440726 B1

TITLE: Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Resnick; Nitzan	Haifa			IL

US-CL-CURRENT: 435/320.1; 435/325, 435/455, 435/69.1, 514/44

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 6. Document ID: US 6379691 B1

L12: Entry 6 of 10

File: USPT

Apr 30, 2002

US-PAT-NO: 6379691

DOCUMENT-IDENTIFIER: US 6379691 B1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tedeschi; Eugene	Santa Rosa	CA		
Shah; Chirag B.	Attleboro	MA		

US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 7. Document ID: US 6171586 B1

L12: Entry 7 of 10

File: USPT

Jan 9, 2001

US-PAT-NO: 6171586

DOCUMENT-IDENTIFIER: US 6171586 B1

TITLE: Antibody formulation

DATE-ISSUED: January 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lam; Xanthe M.	San Francisco	CA		
Oeswein; James Q.	Moss Beach	CA		
Ongpipattanakul; Boonsri	Bangkok			TH
Shahrokh; Zahra	San Francisco	CA		
Wang; Sharon X.	San Mateo	CA		
Weissburg; Robert P.	Greenville	DE		
Wong; Rita L.	San Mateo	CA		

US-CL-CURRENT: 424/130.1; 424/141.1, 424/152.1, 424/154.1, 424/173.1, 530/388.75[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 8. Document ID: US 6013780 A

L12: Entry 8 of 10

File: USPT

Jan 11, 2000

US-PAT-NO: 6013780

DOCUMENT-IDENTIFIER: US 6013780 A

TITLE: VEGF.sub.145 expression vectors

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Neufeld; Gera	Haifa			IL
Keshet; Eli	Kiryat Yam			IL
Vlodavsky; Israel	Mevaseret Zion			IL
Poltorak; Zoya	Jerusalem			IL

US-CL-CURRENT: 536/23.1; 435/320.1

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Drawn Desc](#) [Image](#)

9. Document ID: US 5972894 A

L12: Entry 9 of 10 File: USPT Oct 26, 1999

US-PAT-NO: 5972894

DOCUMENT-IDENTIFIER: US 5972894 A

TITLE: Peptides having potassium channel opener activity

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sinackevich; Nickolai V.	St. Petersburg			RU
Rakhilov; Alexi M.	St. Petersburg			RU
Maslennikov; Sergei V.	St. Petersburg			RU
Green; Lawrence R.	Tacoma	WA		

US-CL-CURRENT: 514/16; 514/19

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Drawn Desc](#) [Image](#)

10. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L12: Entry 10 of 10 File: DWPI Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC) : A61 K 38/00[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw Desc](#) | [Image](#)[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
ISCHEMIC.DWPI,TDBD,EPAB,USPT,PGPB.	14176
ISCHEMICS.DWPI,TDBD,EPAB,USPT,PGPB.	20
CARDIAC.DWPI,TDBD,EPAB,USPT,PGPB.	54732
CARDIACS.DWPI,TDBD,EPAB,USPT,PGPB.	79
(RELAXIN AND (ISCHEMIC SAME CARDIAC)).USPT,PGPB,EPAB,DWPI,TDBD.	10
(RELAXIN AND (ISCHEMIC SAME CARDIAC)).USPT,PGPB,EPAB,DWPI,TDBD.	10

Display Format: [Previous Page](#) [Next Page](#)

WEST

Search Results - Record(s) 1 through 11 of 11 returned.

 1. Document ID: US 20020151681 A1

L11: Entry 1 of 11

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5 2. Document ID: US 20020019349 A1

L11: Entry 2 of 11

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12 3. Document ID: US 20010018418 A1

L11: Entry 3 of 11

File: PGPB

Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018418
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010018418 A1

TITLE: Method of promoting angiogenesis

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unemori, Elaine	Oakland	CA	US	

US-CL-CURRENT: 514/12; 424/43

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)

[KMIC](#) [Draw Desc](#) [Image](#)

4. Document ID: US 6479654 B1

L11: Entry 4 of 11

File: USPT

Nov 12, 2002

US-PAT-NO: 6479654
DOCUMENT-IDENTIFIER: US 6479654 B1

TITLE: Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baird; Andrew	San Diego	CA		
Andreason; Grai	La Jolla	CA		

US-CL-CURRENT: 536/23.5; 435/320.1, 536/23.1

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)

[KMIC](#) [Draw Desc](#) [Image](#)

5. Document ID: US 6440726 B1

L11: Entry 5 of 11

File: USPT

Aug 27, 2002

US-PAT-NO: 6440726
DOCUMENT-IDENTIFIER: US 6440726 B1

TITLE: Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Resnick; Nitzan	Haifa			IL

US-CL-CURRENT: 435/320.1; 435/325, 435/455, 435/69.1, 514/44

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMLC](#) [Draw Desc](#) [Image](#) 6. Document ID: US 6413770 B1

L11: Entry 6 of 11

File: USPT

Jul 2, 2002

US-PAT-NO: 6413770

DOCUMENT-IDENTIFIER: US 6413770 B1

TITLE: NL4 tie ligand homologue nucleic acid

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Godowski; Paul	Burlingame	CA		
Gurney; Austin	Belmont	CA		
Hillan; Kenneth J.	San Francisco	CA		
Botstein; David	Belmont	CA		
Goddard; Audrey	San Francisco	CA		
Roy; Margaret	San Francisco	CA		
Ferrara; Napoleone	San Francisco	CA		
Tumas; Daniel	Orinda	CA		
Schwall; Ralph	Pacifica	CA		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/350,
536/23.1, 536/23.5[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMLC](#) [Draw Desc](#) [Image](#) 7. Document ID: US 6348351 B1

L11: Entry 7 of 11

File: USPT

Feb 19, 2002

US-PAT-NO: 6348351

DOCUMENT-IDENTIFIER: US 6348351 B1

TITLE: Tie receptor tyrosine kinase ligand homologues

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fong; Sherman	Alameda	CA		
Ferrara; Napoleone	San Francisco	CA		
Goddard; Audrey	San Francisco	CA		
Godowski; Paul J.	Burlingame	CA		
Gurney; Austin L.	Belmont	CA		
Hillan; Kenneth	San Francisco	CA		
Williams; P. Mickey	Half Moon Bay	CA		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/350,
536/23.1, 536/23.5

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 8. Document ID: US 6211147 B1

L11: Entry 8 of 11

File: USPT

Apr 3, 2001

US-PAT-NO: 6211147
DOCUMENT-IDENTIFIER: US 6211147 B1TITLE: Method of promoting angiogenesis using relaxin

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unemori; Elaine	Oakland	CA		

US-CL-CURRENT: 514/12; 435/69.1, 530/399[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 9. Document ID: US 6074873 A

L11: Entry 9 of 11

File: USPT

Jun 13, 2000

US-PAT-NO: 6074873
DOCUMENT-IDENTIFIER: US 6074873 A

TITLE: Nucleic acids encoding NL-3

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fong; Sherman	Alameda	CA		
Ferrara; Napoleone	San Francisco	CA		
Goddard; Audrey	San Francisco	CA		
Godowski; Paul J.	Burlingame	CA		
Gurney; Austin L.	Belmont	CA		
Hillan; Kenneth	San Francisco	CA		
Williams; P. Mickey	Half Moon Bay	CA		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/320.1, 435/69.1, 530/350,
536/23.1, 536/23.5[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 10. Document ID: WO 9706814 A1

L11: Entry 10 of 11

File: EPAB

Feb 27, 1997

PUB-NO: WO009706814A1
DOCUMENT-IDENTIFIER: WO 9706814 A1
TITLE: METHOD OF PROMOTING ANGIOGENESIS

PUBN-DATE: February 27, 1997

INVENTOR- INFORMATION:

NAME	COUNTRY
UNEMORI, ELAINE	

INT-CL (IPC): A61 K 38/00

EUR-CL (EPC): A61K038/22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

11. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L11: Entry 11 of 11

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
ISCHEMIC.DWPI,TDBD,EPAB,USPT,PGPB.	14176
ISCHEMICS.DWPI,TDBD,EPAB,USPT,PGPB.	20
WOUND.DWPI,TDBD,EPAB,USPT,PGPB.	353041
WOUNDS.DWPI,TDBD,EPAB,USPT,PGPB.	17941
(RELAXIN AND (ISCHEMIC SAME WOUND)).USPT,PGPB,EPAB,DWPI,TDBD.	11
(RELAXIN AND (ISCHEMIC SAME WOUND)).USPT,PGPB,EPAB,DWPI,TDBD.	11

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#) | [Cases](#)**Search Results -**

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
STROKE?	0
STROKEA.DWPI,TDBD,EPAB,USPT,PGPB.	2
STROKEB.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKED.DWPI,TDBD,EPAB,USPT,PGPB.	2774
STROKEE.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKEL.DWPI,TDBD,EPAB,USPT,PGPB.	1
STROKEN.DWPI,TDBD,EPAB,USPT,PGPB.	10
STROKER.DWPI,TDBD,EPAB,USPT,PGPB.	187
STROKES.DWPI,TDBD,EPAB,USPT,PGPB.	39254
(RELAXIN AND STROKE?).USPT,PGPB,EPAB,DWPI,TDBD.	9


[There are more results than shown above. Click here to view the entire set.](#)

Database:

- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text  Clear

Search History**DATE: Wednesday, November 13, 2002** [Printable Copy](#) [Create Case](#)

WEST

Search Results - Record(s) 1 through 8 of 8 returned.

 1. Document ID: US 20020151681 A1

L9: Entry 1 of 8

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020151681

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020151681 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Craig A.	Laytonsville	MD	US	
Ruben, Steven M.	Olney	MD	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.3, 536/23.5 2. Document ID: US 20020122814 A1

L9: Entry 2 of 8

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/426; 424/718, 427/2.24 3. Document ID: US 20020045210 A1

L9: Entry 3 of 8

File: PGPB

Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045210

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020045210 A1

TITLE: Neuropeptide-like polypeptide zpep17

PUBLICATION-DATE: April 18, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheppard, Paull O.	Granite Falls	WA	US	
Bishop, Paul D.	Fall City	WA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

4. Document ID: US 20020022046 A1

L9: Entry 4 of 8

File: PGPB

Feb 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/423

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

5. Document ID: US 20020019349 A1

L9: Entry 5 of 8

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw. Desc](#) | [Image](#) 6. Document ID: US 20010021380 A1

L9: Entry 6 of 8

File: PGPB

Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021380

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010021380 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pluennenke, John D.	Kansas City	MO	US	

US-CL-CURRENT: 424/131.1; 514/171, 514/44[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw. Desc](#) | [Image](#) 7. Document ID: US 6379691 B1

L9: Entry 7 of 8

File: USPT

Apr 30, 2002

US-PAT-NO: 6379691

DOCUMENT-IDENTIFIER: US 6379691 B1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tedeschi; Eugene	Santa Rosa	CA		
Shah; Chirag B.	Attleboro	MA		

US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw. Desc](#) | [Image](#) 8. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L9: Entry 8 of 8

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000),
2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
PULMONARY.DWPI,TDBD,EPAB,USPT,PGPB.	30215
PULMONARIES	0
PULMONARYS	0
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
(RELAXIN AND (HYPERTENSION SAME PULMONARY)).USPT,PGPB,EPAB,DWPI,TDBD.	8
(RELAXIN AND (PULMONARY SAME HYPERTENSION)).USPT,PGPB,EPAB,DWPI,TDBD.	8

Display Format:

[Previous Page](#) [Next Page](#)

WEST

[Generate Collection](#)[Print](#)

Search Results - Record(s) 1 through 13 of 13 returned.

 1. Document ID: US 20020031513 A1

L10: Entry 1 of 13

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv	IL		

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#) 2. Document ID: US 20020019349 A1

L10: Entry 2 of 13

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR- INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#) 3. Document ID: US 20010021380 A1

L10: Entry 3 of 13

File: PGPB

Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021380
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010021380 A1

TITLE: Soluble tumor necrosis factor receptor treatment of medical disorders

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pluenneke, John D.	Kansas City	MO	US	

US-CL-CURRENT: 424/131.1; 514/171, 514/44

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

4. Document ID: US 6468770 B1

L10: Entry 4 of 13

File: USPT

Oct 22, 2002

US-PAT-NO: 6468770

DOCUMENT-IDENTIFIER: US 6468770 B1

TITLE: Nucleic acids and proteins of *D. melanogaster* insulin-like genes and uses thereof

DATE-ISSUED: October 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keyes; Linda Nolan	San Carlos	CA		
Doberstein; Stephen Kohl	San Francisco	CA		
Buchman; Andrew Roy	Berkeley	CA		
Reddy; Bindu Priya	San Francisco	CA		
Ruddy; David Andrew	San Francisco	CA		

US-CL-CURRENT: 435/69.4; 435/320.1, 435/325, 435/455, 435/471, 435/69.1, 536/23.1,
536/23.5, 536/23.51

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

5. Document ID: US 6410708 B1

L10: Entry 5 of 13

File: USPT

Jun 25, 2002

US-PAT-NO: 6410708

DOCUMENT-IDENTIFIER: US 6410708 B1

TITLE: Nucleic acids encoding A-33 related antigen polypeptides

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi	San Mateo	CA		
Fong; Sherman	Alameda	CA		
Goddard; Audrey	San Francisco	CA		
Gurney; Austin L.	Belmont	CA		
Napier; Mary A.	Hillsborough	CA		
Tumas; Daniel	Orinda	CA		
Wood; William I.	Hillsborough	CA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/252.33, 435/254.2, 435/320.1, 435/348,
435/358, 435/455, 435/471, 435/69.1, 435/71.1, 435/71.2, 536/23.1

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

6. Document ID: US 6135942 A

L10: Entry 6 of 13

File: USPT

Oct 24, 2000

US-PAT-NO: 6135942

DOCUMENT-IDENTIFIER: US 6135942 A

TITLE: Nucleic acids proteins of a *D. melanogaster* insulin-like gene and uses thereof

DATE-ISSUED: October 24, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Leptin; Maria	Cologne			DE

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/348, 435/69.1, 435/69.4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

7. Document ID: US 6114304 A

L10: Entry 7 of 13

File: USPT

Sep 5, 2000

US-PAT-NO: 6114304

DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Young; Andrew A.	Alpine	CA		
Rink; Timothy J.	La Jolla	CA		
Brown; Kathleen Ann Keiting	Wake Forest	NC		

US-CL-CURRENT: 514/12; 514/3

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Drawn Desc](#) [Image](#) 8. Document ID: US 5795861 A

L10: Entry 8 of 13

File: USPT

Aug 18, 1998

US-PAT-NO: 5795861

DOCUMENT-IDENTIFIER: US 5795861 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13, 514/866, 530/307, 530/327[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Drawn Desc](#) [Image](#) 9. Document ID: US 5376638 A

L10: Entry 9 of 13

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Drawn Desc](#) [Image](#) 10. Document ID: US 5364841 A

L10: Entry 10 of 13

File: USPT

Nov 15, 1994

US-PAT-NO: 5364841

DOCUMENT-IDENTIFIER: US 5364841 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: November 15, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KWD](#) | [Drawn Desc](#) | [Image](#)

11. Document ID: US 5280014 A

L10: Entry 11 of 13

File: USPT

Jan 18, 1994

US-PAT-NO: 5280014

DOCUMENT-IDENTIFIER: US 5280014 A

TITLE: Treatment of obesity and essential hypertension and related disorders

DATE-ISSUED: January 18, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Leighton; Brendan	Eynsham			GB2

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 514/17, 514/4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KWD](#) | [Drawn Desc](#) | [Image](#)

12. Document ID: US 4423037 A

L10: Entry 12 of 13

File: USPT

Dec 27, 1983

US-PAT-NO: 4423037

DOCUMENT-IDENTIFIER: US 4423037 A

TITLE: Inhibitors of peptide hormone action

DATE-ISSUED: December 27, 1983

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rosenblatt; Michael	Newton Highlands	MA		
Potts, Jr.; John T.	West Newton	MA		

US-CL-CURRENT: 514/12; 530/324, 530/334, 930/10, 930/20, 930/21, 930/DIG.821

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KWD](#) | [Drawn Desc](#) | [Image](#)

13. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L10: Entry 13 of 13

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KDDC](#) | [Draw Desc](#) | [Image](#)

[Generate Collection](#)

[Print](#)

Term	Documents
RELAXIN,DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
RENAL,DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
(RELAXIN AND (HYPERTENSION SAME RENAL)).USPT,PGPB,EPAB,DWPI,TDBD.	13
(RELAXIN AND (RENAL SAME HYPERTENSION)).USPT,PGPB,EPAB,DWPI,TDBD.	13

Display Format:

[Previous Page](#) [Next Page](#)

WEST

Search Results - Record(s) 1 through 3 of 3 returned.

 1. Document ID: US 20020045210 A1

L8: Entry 1 of 3

File: PGPB

Apr 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020045210

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020045210 A1

TITLE: Neuropeptide-like polypeptide zpep17

PUBLICATION-DATE: April 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheppard, Paull O.	Granite Falls	WA	US	
Bishop, Paul D.	Fall City	WA	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 536/23.1 2. Document ID: US 20020031513 A1

L8: Entry 2 of 3

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv		IL	

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575 3. Document ID: US 5376638 A

L8: Entry 3 of 3

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
RENAL.DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
FUNCTION?	0
FUNCTIONA.DWPI,TDBD,EPAB,USPT,PGPB.	169
FUNCTIONB.DWPI,TDBD,EPAB,USPT,PGPB.	9
FUNCTIONC.DWPI,TDBD,EPAB,USPT,PGPB.	2
FUNCTIOND.DWPI,TDBD,EPAB,USPT,PGPB.	4
(RELAXIN AND HYPERTENSION AND (RENAL SAME FUNCTION?)).USPT,PGPB,EPAB,DWPI,TDBD.	3

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:	<input type="button" value="-"/>	Change Format
---------------------------------	----------------------------------	-------------------------------

Previous Page	Next Page
-------------------------------	---------------------------

WEST

Search Results - Record(s) 1 through 2 of 2 returned.

 1. Document ID: US 20020031513 A1

L7: Entry 1 of 2

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv		IL	

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575 2. Document ID: US 5376638 A

L7: Entry 2 of 2

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
VASODILATION.DWPI,TDBD,EPAB,USPT,PGPB.	3926
VASODILATIONS.DWPI,TDBD,EPAB,USPT,PGPB.	11
HYPERTENSION.DWPI,TDBD,EPAB,USPT,PGPB.	31123
HYPERTENSIONS.DWPI,TDBD,EPAB,USPT,PGPB.	111
RENAL.DWPI,TDBD,EPAB,USPT,PGPB.	29674
RENALS.DWPI,TDBD,EPAB,USPT,PGPB.	69
VASODILATOR?	0
VASODILATORS.DWPI,TDBD,EPAB,USPT,PGPB.	5737
VASODILATORY.DWPI,TDBD,EPAB,USPT,PGPB.	1942
(RELAXIN AND (VASODILATION OR VASODILATOR?)AND HYPERTENSION AND (RENAL SAME FUNCTION?)).USPT,PGPB,EPAB,DWPI,TDBD.	2

[There are more results than shown above. Click here to view the entire set.](#)

Display Format:

[Previous Page](#) [Next Page](#)

WEST

Search Results - Record(s) 1 through 47 of 47 returned.

 1. Document ID: US 20020164372 A1

L5: Entry 1 of 47

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164372

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164372 A1

TITLE: Controlled release systems for polymers

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Pestka, Sidney	North Caldwell	NJ	US	

US-CL-CURRENT: 424/469; 514/2 2. Document ID: US 20020122814 A1

L5: Entry 2 of 47

File: PGPB

Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020122814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020122814 A1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/426; 424/718, 427/2.24 3. Document ID: US 20020068814 A1

L5: Entry 3 of 47

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068814

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068814 A1

TITLE: Peptide antagonists of CGRP-receptor superfamily and methods of use

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Derek David	Omaha	NE	US	
Saha, Shankar	Indianapolis	IN	US	
Abel, Peter W.	Omaha	NE	US	

US-CL-CURRENT: 530/326; 435/7.1

[KMC](#) | [Draw Desc](#) | [Image](#)

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

4. Document ID: US 20020031513 A1

Mar 14, 2002

L5: Entry 4 of 47

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20020031513

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020031513 A1

TITLE: Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Leibovitz, Shamir	Tel Aviv	IL		

US-CL-CURRENT: 424/141.1; 514/509, 514/562, 514/565, 514/575

[KMC](#) | [Draw Desc](#) | [Image](#)

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

5. Document ID: US 20020022046 A1

Feb 21, 2002

L5: Entry 5 of 47

File: PGPB

PGPUB-DOCUMENT-NUMBER: 20020022046

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020022046 A1

TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRICIOUS, NITRIC OXIDE-RELEASING COATING

PUBLICATION-DATE: February 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tedeschi, Eugene	Santa Rosa	CA	US	
Shah, Chirag B.	North Attleboro	MA	US	

US-CL-CURRENT: 424/423

[KMC](#) | [Draw Desc](#) | [Image](#)

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

6. Document ID: US 20020019349 A1
L5: Entry 6 of 47

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019349 A1

TITLE: Use of relaxin treat diseases related to vasoconstriction

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conrad, Kirk P.	Cranberry Township	PA	US	
Lewis, Martyn	Menlo park	CA	US	
Unemori, Elaine N.	Oakland	CA	US	
Huang, Xinfan	Menlo Park	CA	US	
Tozzi, Carol A.	Jackson	NJ	US	

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMPC	Drawn Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------------	-------

7. Document ID: US 20020010208 A1

L5: Entry 7 of 47

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010208

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010208 A1

TITLE: Dha-pharmaceutical agent conjugates of taxanes

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shashoua, Victor	Brookline	MA	US	
Swindell, Charles	Merion	PA	US	
Webb, Nigel	Bryn Mawr	PA	US	
Bradley, Matthews	Layton	PA	US	

US-CL-CURRENT: 514/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMPC	Drawn Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------------	-------

8. Document ID: US 20020004065 A1

L5: Entry 8 of 47

File: PGPB

Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004065

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004065 A1

TITLE: Compositions and methods to effect the release profile in the transdermal administration of active agents

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kanios, David	Miami	FL	US	

US-CL-CURRENT: 424/449

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

9. Document ID: US 20010023254 A1

L5: Entry 9 of 47

File: PGPB

Sep 20, 2001

PGPUB-DOCUMENT-NUMBER: 20010023254

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010023254 A1

TITLE: Use of sulfamate derivatives for treating impulse control disorders

PUBLICATION-DATE: September 20, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
McElroy, Susan L.	Cincinnati	OH	US	

US-CL-CURRENT: 514/439

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

10. Document ID: US 20010002404 A1

L5: Entry 10 of 47

File: PGPB

May 31, 2001

PGPUB-DOCUMENT-NUMBER: 20010002404

PGPUB-FILING-TYPE: new-utility

DOCUMENT-IDENTIFIER: US 20010002404 A1

TITLE: Fatty acid-pharmaceutical agent conjugates

PUBLICATION-DATE: May 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Webb, Nigel L.	Bryn Mawr	PA	US	
Bradley, Matthews O.	Laytonsville	MD	US	
Swindell, Charles S.	Merion	PA	US	
Shashoua, Victor E.	Brookline	MA	US	

US-CL-CURRENT: 514/560; 514/558

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

11. Document ID: US 6479630 B1

L5: Entry 11 of 47

File: USPT

Nov 12, 2002

US-PAT-NO: 6479630

DOCUMENT-IDENTIFIER: US 6479630 B1

TITLE: Human purinergic P2U receptor

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coleman; Roger	Mountain View	CA		
Au-Young; Janice	Berkeley	CA		
Stuart; Susan G.	Montara	CA		
Guegler; Karl J.	Menlo Park	CA		

US-CL-CURRENT: 530/350; 530/326, 930/10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Drawn Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------------	-------

 12. Document ID: US 6379691 B1

L5: Entry 12 of 47

File: USPT

Apr 30, 2002

US-PAT-NO: 6379691

DOCUMENT-IDENTIFIER: US 6379691 B1

TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating

DATE-ISSUED: April 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tedeschi; Eugene	Santa Rosa	CA		
Shah; Chirag B.	Attleboro	MA		

US-CL-CURRENT: 424/423; 424/422, 424/78.08, 514/824

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Drawn Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------------	-------

 13. Document ID: US 6323236 B1

L5: Entry 13 of 47

File: USPT

Nov 27, 2001

US-PAT-NO: 6323236

DOCUMENT-IDENTIFIER: US 6323236 B1

TITLE: Use of sulfamate derivatives for treating impulse control disorders

DATE-ISSUED: November 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McElroy; Susan	Cincinnati	OH		

US-CL-CURRENT: 514/439; 514/455, 514/459, 514/463

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

14. Document ID: US 6268474 B1

L5: Entry 14 of 47

File: USPT

Jul 31, 2001

US-PAT-NO: 6268474

DOCUMENT-IDENTIFIER: US 6268474 B1

TITLE: Peptide antagonists of CGRP-receptor superfamily and methods of use

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Smith; Derek David	Omaha	NE		
Saha; Shankar	Indianapolis	IN		
Abel; Peter W.	Omaha	NE		

US-CL-CURRENT: 530/326; 530/300, 530/307

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

15. Document ID: US 6258550 B1

L5: Entry 15 of 47

File: USPT

Jul 10, 2001

US-PAT-NO: 6258550

DOCUMENT-IDENTIFIER: US 6258550 B1

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: July 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 435/7.1; 435/183, 530/300

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	---------------------------	-----------------------

16. Document ID: US 6221383 B1

L5: Entry 16 of 47

File: USPT

Apr 24, 2001

US-PAT-NO: 6221383

DOCUMENT-IDENTIFIER: US 6221383 B1

TITLE: Solubility parameter based drug delivery system and method for altering drug saturation concentration

DATE-ISSUED: April 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miranda; Jesus	Miami	FL		
Sablotsky; Steven	Miami	FL		

US-CL-CURRENT: 424/449; 424/448

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

17. Document ID: US 6147189 A

L5: Entry 17 of 47

File: USPT

Nov 14, 2000

US-PAT-NO: 6147189

DOCUMENT-IDENTIFIER: US 6147189 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/333; 530/328, 548/533

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

18. Document ID: US 6114304 A

L5: Entry 18 of 47

File: USPT

Sep 5, 2000

US-PAT-NO: 6114304

DOCUMENT-IDENTIFIER: US 6114304 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: September 5, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Young; Andrew A.	Alpine	CA		
Rink; Timothy J.	La Jolla	CA		
Brown; Kathleen Ann Keiting	Wake Forest	NC		

US-CL-CURRENT: 514/12; 514/3[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw Desc](#) | [Image](#) 19. Document ID: US 6111069 A

L5: Entry 19 of 47

File: USPT

Aug 29, 2000

US-PAT-NO: 6111069

DOCUMENT-IDENTIFIER: US 6111069 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: August 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/333; 530/328, 548/533[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw Desc](#) | [Image](#) 20. Document ID: US 6100044 A

L5: Entry 20 of 47

File: USPT

Aug 8, 2000

US-PAT-NO: 6100044

DOCUMENT-IDENTIFIER: US 6100044 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 435/7.1; 436/501, 514/12, 514/13, 514/2, 548/533[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KMC](#) | [Draw Desc](#) | [Image](#) 21. Document ID: US 6084066 A

L5: Entry 21 of 47

File: USPT

Jul 4, 2000

US-PAT-NO: 6084066

DOCUMENT-IDENTIFIER: US 6084066 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: July 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			IN

US-CL-CURRENT: 530/333; 530/329, 548/533

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

22. Document ID: US 6075005 A

L5: Entry 22 of 47

File: USPT

Jun 13, 2000

US-PAT-NO: 6075005

DOCUMENT-IDENTIFIER: US 6075005 A

TITLE: Medicaments comprising relaxin and their use

DATE-ISSUED: June 13, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lurie; Raziel	Tel Aviv			IL

US-CL-CURRENT: 514/2; 514/275, 514/284

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

23. Document ID: US 6024976 A

L5: Entry 23 of 47

File: USPT

Feb 15, 2000

US-PAT-NO: 6024976

DOCUMENT-IDENTIFIER: US 6024976 A

TITLE: Solubility parameter based drug delivery system and method for altering drug saturation concentration

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miranda; Jesus	Miami	FL		
Sablotsky; Steven	Miami	FL		

US-CL-CURRENT: 424/449; 424/448

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

24. Document ID: US 6008039 A

L5: Entry 24 of 47

File: USPT

Dec 28, 1999

US-PAT-NO: 6008039

DOCUMENT-IDENTIFIER: US 6008039 A

TITLE: Polynucleotide encoding a novel purinergic P.sub.2U receptor

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coleman; Roger	Mountain View	CA		
Au-Young; Janice	Berkeley	CA		
Stuart; Susan G.	Montara	CA		
Guegler; Karl J.	Menlo Park	CA		

US-CL-CURRENT: 435/325; 435/320.1, 435/91.2, 536/23.1, 536/23.5[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 25. Document ID: US 5972894 A

L5: Entry 25 of 47

File: USPT

Oct 26, 1999

US-PAT-NO: 5972894

DOCUMENT-IDENTIFIER: US 5972894 A

TITLE: Peptides having potassium channel opener activity

DATE-ISSUED: October 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sinackevich; Nickolai V.	St. Petersburg			RU
Rakhilov; Alexi M.	St. Petersburg			RU
Maslennikov; Sergei V.	St. Petersburg			RU
Green; Lawrence R.	Tacoma	WA		

US-CL-CURRENT: 514/16; 514/19[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 26. Document ID: US 5965698 A

L5: Entry 26 of 47

File: USPT

Oct 12, 1999

US-PAT-NO: 5965698

DOCUMENT-IDENTIFIER: US 5965698 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: October 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/326; 530/300, 530/324, 530/333, 530/380, 548/533

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

27. Document ID: US 5955284 A

L5: Entry 27 of 47

File: USPT

Sep 21, 1999

US-PAT-NO: 5955284

DOCUMENT-IDENTIFIER: US 5955284 A

TITLE: Assay method to detect serpin derived from human hypothalamus

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Braxton; Scott Michael	San Mateo	CA		
Diep; Dinh	San Francisco	CA		
Stuart; Susan G.	Montara	CA		

US-CL-CURRENT: 435/6; 536/23.1, 536/24.31

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

28. Document ID: US 5952465 A

L5: Entry 28 of 47

File: USPT

Sep 14, 1999

US-PAT-NO: 5952465

DOCUMENT-IDENTIFIER: US 5952465 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/333; 424/185.1, 424/278.1, 530/326, 530/327, 530/328, 548/533

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#) | [KMC](#) | [Draw Desc](#) | [Image](#)

29. Document ID: US 5952296 A

L5: Entry 29 of 47

File: USPT

Sep 14, 1999

US-PAT-NO: 5952296

DOCUMENT-IDENTIFIER: US 5952296 A

TITLE: Method of using relaxin as therapeutic or preventing agent

DATE-ISSUED: September 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bigazzi; Mario	Florence			IT

US-CL-CURRENT: 514/3; 514/12, 514/822, 514/885[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 30. Document ID: US 5948887 A

L5: Entry 30 of 47

File: USPT

Sep 7, 1999

US-PAT-NO: 5948887

DOCUMENT-IDENTIFIER: US 5948887 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: September 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 530/333; 548/533[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 31. Document ID: US 5929210 A

L5: Entry 31 of 47

File: USPT

Jul 27, 1999

US-PAT-NO: 5929210

DOCUMENT-IDENTIFIER: US 5929210 A

TITLE: Serpin derived from human hypothalamus

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Braxton; Scott Michael	San Mateo	CA		
Diep; Dinh	San Francisco	CA		
Stuart; Susan G.	Montara	CA		

US-CL-CURRENT: 530/350

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 32. Document ID: US 5928896 A

L5: Entry 32 of 47

File: USPT

Jul 27, 1999

US-PAT-NO: 5928896

DOCUMENT-IDENTIFIER: US 5928896 A

TITLE: Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site

DATE-ISSUED: July 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Herbert J.	Richmond	VA		
Kini; R. Manjunatha	Singapore			SG

US-CL-CURRENT: 435/69.1; 435/91.2, 530/300, 530/324[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 33. Document ID: US 5795909 A

L5: Entry 33 of 47

File: USPT

Aug 18, 1998

US-PAT-NO: 5795909

DOCUMENT-IDENTIFIER: US 5795909 A

TITLE: DHA-pharmaceutical agent conjugates of taxanes

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shashoua; Victor E.	Brookline	MA		
Swindell; Charles S.	Merion	PA		
Webb; Nigel L.	Bryn Mawr	PA		
Bradley; Matthews O.	Laytonsville	MD		

US-CL-CURRENT: 514/449; 514/549[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 34. Document ID: US 5795861 A

L5: Entry 34 of 47

File: USPT

Aug 18, 1998

US-PAT-NO: 5795861

DOCUMENT-IDENTIFIER: US 5795861 A

TITLE: Methods for regulating gastrointestinal motility

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kolterman; Orville G.	Poway	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13, 514/866, 530/307, 530/327

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

35. Document ID: US 5719197 A

L5: Entry 35 of 47

File: USPT

Feb 17, 1998

US-PAT-NO: 5719197

DOCUMENT-IDENTIFIER: US 5719197 A

TITLE: Compositions and methods for topical administration of pharmaceutically active agents

DATE-ISSUED: February 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kanios; David P.	Miami	FL		
Gentile; Joseph A.	Plantation	FL		
Mantelle; Juan A.	Miami	FL		
Sablotsky; Steven	Miami	FL		

US-CL-CURRENT: 514/772.6; 424/435, 424/443, 514/781, 514/782

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

36. Document ID: US 5700924 A

L5: Entry 36 of 47

File: USPT

Dec 23, 1997

US-PAT-NO: 5700924

DOCUMENT-IDENTIFIER: US 5700924 A

TITLE: Serpin derived from human hypothalamus

DATE-ISSUED: December 23, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Braxton; Scott Michael	San Mateo	CA		
Diep; Dinh	San Francisco	CA		
Stuart; Susan G.	Montara	CA		

US-CL-CURRENT: 536/23.1; 435/320.1, 435/69.1, 435/91.4

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

37. Document ID: US 5677279 A

L5: Entry 37 of 47

File: USPT

Oct 14, 1997

US-PAT-NO: 5677279

DOCUMENT-IDENTIFIER: US 5677279 A

TITLE: Methods and compositions for treating pain with amylin or agonists thereof

DATE-ISSUED: October 14, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	----------------------------	-----------------------

 38. Document ID: US 5656286 A

L5: Entry 38 of 47

File: USPT

Aug 12, 1997

US-PAT-NO: 5656286

DOCUMENT-IDENTIFIER: US 5656286 A

TITLE: Solubility parameter based drug delivery system and method for altering drug saturation concentration

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miranda; Jesus	Miami	FL		
Sablotsky; Steven	Miami	FL		

US-CL-CURRENT: 424/449; 424/448

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC	Drawn Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	---------------------	----------------------------	-----------------------

 39. Document ID: US 5637309 A

L5: Entry 39 of 47

File: USPT

Jun 10, 1997

US-PAT-NO: 5637309

DOCUMENT-IDENTIFIER: US 5637309 A

TITLE: Physiologically active substance-prolonged releasing-type pharmaceutical preparation

DATE-ISSUED: June 10, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tajima; Masahiro	Yokohama			JP
Yoshimoto; Takashi	Sendai			JP
Fukushima; Shoji	Yokohama			JP
Kaminuma; Toshihiko	Yokohama			JP
Ehama; Ritsuko	Tokyo			JP
Baba; Takaaki	Yokohama			JP
Watabe; Kazuo	Yokohama			JP

US-CL-CURRENT: 424/423; 424/426, 424/457, 424/468, 514/772.3, 514/777, 514/781,
514/784, 514/785, 514/808, 514/929

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

40. Document ID: US 5478807 A

L5: Entry 40 of 47

File: USPT

Dec 26, 1995

US-PAT-NO: 5478807

DOCUMENT-IDENTIFIER: US 5478807 A

TITLE: Use of relaxin in the treatment of bradycardia

DATE-ISSUED: December 26, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cronin; Michael	San Mateo	CA		
Osheroff; Phyllis L.	Woodside	CA		
Thomas; G. Roger	Burlingame	CA		
Ward; David G.	Oakdale	CA		

US-CL-CURRENT: 514/12; 530/324

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [KMC](#) [Draw Desc](#) [Image](#)

41. Document ID: US 5446070 A

L5: Entry 41 of 47

File: USPT

Aug 29, 1995

US-PAT-NO: 5446070

DOCUMENT-IDENTIFIER: US 5446070 A

TITLE: Compositions and methods for topical administration of pharmaceutically active agents

DATE-ISSUED: August 29, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mantelle; Juan A.	Miami	FL		

US-CL-CURRENT: 514/772.6; 424/485, 424/486, 424/487, 424/488, 514/781, 514/782

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 42. Document ID: US 5376638 A

L5: Entry 42 of 47

File: USPT

Dec 27, 1994

US-PAT-NO: 5376638

DOCUMENT-IDENTIFIER: US 5376638 A

TITLE: Methods for treating renin-related disorders with amylin antagonists

DATE-ISSUED: December 27, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Young; Andrew A.	San Diego	CA		
Rink; Timothy J.	La Jolla	CA		

US-CL-CURRENT: 514/12; 514/11, 514/13[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 43. Document ID: US 5288623 A

L5: Entry 43 of 47

File: USPT

Feb 22, 1994

US-PAT-NO: 5288623

DOCUMENT-IDENTIFIER: US 5288623 A

TITLE: Process for secretory production of a calcium-binding protein

DATE-ISSUED: February 22, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zenno; Shuhei	Yokohama			JP
Inouye; Satoshi	San Diego	CA		

US-CL-CURRENT: 435/69.7; 435/252.3, 435/320.1[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KMC](#) [Draw Desc](#) [Image](#) 44. Document ID: US 5264372 A

L5: Entry 44 of 47

File: USPT

Nov 23, 1993

US-PAT-NO: 5264372

DOCUMENT-IDENTIFIER: US 5264372 A

TITLE: Receptor-based screening methods for amylin agonists and antagonists

DATE-ISSUED: November 23, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beaumont; Kevin	San Diego	CA		
Rink; Timothy J.	San Diego	CA		

US-CL-CURRENT: 436/504; 436/501, 436/503

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

45. Document ID: US 5166191 A

L5: Entry 45 of 47

File: USPT

Nov 24, 1992

US-PAT-NO: 5166191

DOCUMENT-IDENTIFIER: US 5166191 A

TITLE: Use of relaxin in cardiovascular therapy

DATE-ISSUED: November 24, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cronin; Michael	San Mateo	CA		
Osherooff; Phyllis L.	Woodside	CA		
Ward; David G.	Oakdale	CA		

US-CL-CURRENT: 514/12; 530/324

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

46. Document ID: US 2002019349 A1 WO 200158468 A1 AU 200136886 A

L5: Entry 46 of 47

File: DWPI

Feb 14, 2002

DERWENT-ACC-NO: 2001-514619

DERWENT-WEEK: 200214

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin

INVENTOR: CONRAD, K P; HUANG, X ; LEWIS, M ; TOZZI, C A ; UNEMORI, E N

PRIORITY-DATA: 2000US-242216P (October 20, 2000), 2000US-181408P (February 9, 2000), 2000US-200284P (April 28, 2000), 2001US-0780752 (February 9, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2002019349 A1	February 14, 2002		000	A61K038/00
WO 200158468 A1	August 16, 2001	E	073	A61K038/00
AU 200136886 A	August 20, 2001		000	A61K038/00

INT-CL (IPC): A61 K 38/00

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)

[KMC](#) | [Draw Desc](#) | [Image](#)

47. Document ID: US 2001002404 A1

L5: Entry 47 of 47

File: DWPI

May 31, 2001

DERWENT-ACC-NO: 2001-366605

DERWENT-WEEK: 200138

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Targeting pharmaceutical agents to non-central nervous system tissues to treat e.g. psoriasis by administering covalent conjugates of unbranched naturally occurring fatty acid and pharmaceutical agent

INVENTOR: BRADLEY, M O; SHASHOUA, V E ; SWINDELL, C S ; WEBB, N L

PRIORITY-DATA: 1996US-0651428 (May 22, 1996), 2000US-0730450 (December 5, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 2001002404 A1	May 31, 2001		043	A61K031/20

INT-CL (IPC): A61 K 31/20
[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)
[KWD](#) | [Draw Desc](#) | [Image](#)
[Generate Collection](#)[Print](#)

Term	Documents
RELAXIN.DWPI,TDBD,EPAB,USPT,PGPB.	655
RELAXINS.DWPI,TDBD,EPAB,USPT,PGPB.	49
VASODILATION.DWPI,TDBD,EPAB,USPT,PGPB.	3926
VASODILATIONS.DWPI,TDBD,EPAB,USPT,PGPB.	11
VASODILATOR?	0
VASODILATORS.DWPI,TDBD,EPAB,USPT,PGPB.	5737
VASODILATORY.DWPI,TDBD,EPAB,USPT,PGPB.	1942
VASODILATOR:.DWPI,TDBD,EPAB,USPT,PGPB.	9
(RELAXIN AND (VASODILATION OR VASODILATOR?)).USPT,PGPB,EPAB,DWPI,TDBD.	47
(RELAXIN AND (VASODILATION OR VASODILATOR?)).USPT,PGPB,EPAB,DWPI,TDBD.	47

Display Format:
[Previous Page](#) [Next Page](#)

WEST Search History

DATE: Wednesday, November 13, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
L13	relaxin and stroke?	9	L13
L12	relaxin and (ischemic same cardiac)	10	L12
L11	relaxin and (ischemic same wound)	11	L11
L10	relaxin and (renal same hypertension)	13	L10
L9	relaxin and (pulmonary same hypertension)	8	L9
L8	relaxin and hypertension and (renal same function?)	3	L8
L7	relaxin and (vasodilation or vasodilator?)and hypertension and (renal same function?)	2	L7
L6	relaxin and (vasodilation or vasodilator?)and hypertension	17	L6
L5	relaxin and (vasodilation or vasodilator?)	47	L5
L4	5166191.pn.	2	L4
L3	08050745.ap.	0	L3
L2	unemori-elaine.in.	7	L2
L1	unemori-elaine-n\$.in.	1	L1

END OF SEARCH HISTORY

FILE 'HOME' ENTERED AT 16:07:32 ON 13 NOV 2002

=> index medicine bioscience meetings
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
1.26	1.26

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS,
CEN, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU,
EMBAL, EMBASE, ESBIOBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI,
MEDICONF, MEDLINE, NAPRALERT, NLDB, ...' ENTERED AT 16:10:47 ON 13 NOV 2002

78 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (relaxin same recombinant or relaxin) and hypertension and (ischemic or ischemia)
and vasodilation
1 FILE CAPLUS
26 FILE DGENE
16 FILES SEARCHED...
2 FILE IFIPAT
30 FILES SEARCHED...
5 FILE USPATFULL
1 FILE USPAT2
48 FILES SEARCHED...
1 FILE WPIDS
66 FILES SEARCHED...
1 FILE WPINDEX

7 FILES HAVE ONE OR MORE ANSWERS, 78 FILES SEARCHED IN STNINDEX

L1 QUE (RELAXIN SAME RECOMBINANT OR RELAXIN) AND HYPERTENSION AND (ISCHEMIC OR
ISCHEMIA) AND VASODILATION

=> file hits
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
13.78	15.04

FILE 'DGENE' ENTERED AT 16:26:19 ON 13 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'USPATFULL' ENTERED AT 16:26:19 ON 13 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 16:26:19 ON 13 NOV 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'CAPLUS' ENTERED AT 16:26:19 ON 13 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:26:19 ON 13 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:26:19 ON 13 NOV 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s 11
L2 26 FILE DGENE

L3 5 FILE USPATFULL
L4 2 FILE IFIPAT
L5 1 FILE CAPLUS
L6 1 FILE USPAT2
L7 1 FILE WPIIDS

TOTAL FOR ALL FILES
L8 36 L1

=> dup rem 18
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L8
L9 32 DUP REM L8 (4 DUPLICATES REMOVED)

=> d 19 1-32 ibib abs

L9 ANSWER 1 OF 32 USPATFULL DUPLICATE 1
ACCESSION NUMBER: 2002:37330 USPATFULL
TITLE: USES FOR MEDICAL DEVICES HAVING A LUBRIFICIOUS, NITRIC
OXIDE-RELEASING COATING
INVENTOR(S): Tedeschi, Eugene, Santa Rosa, CA, UNITED STATES
Shah, Chirag B., North Attleboro, MA, UNITED STATES
PATENT ASSIGNEE(S): Arterial Vascular Engineering, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002022046	A1	20020221
	US 6379691	B2	20020430
APPLICATION INFO.:	US 2000-726856	A1	20001130 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-405024, filed on 27 Sep 1999, GRANTED, Pat. No. US 6218016 Continuation-in-part of Ser. No. US 1998-163038, filed on 29 Sep 1998, GRANTED, Pat. No. US 6299980		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MEDTRONIC AVE, INC., 3576 UNOCAL PLACE, SANTA ROSA, CA, 95403		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1240		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 32 USPATFULL DUPLICATE 2
ACCESSION NUMBER: 2002:32527 USPATFULL
TITLE: Use of relaxin treat diseases related to
vasoconstriction
INVENTOR(S): Conrad, Kirk P., Cranberry Township, PA, UNITED STATES
Lewis, Martyn, Menlo park, CA, UNITED STATES
Unemori, Elaine N., Oakland, CA, UNITED STATES
Huang, Xinfan, Menlo Park, CA, UNITED STATES

Tozzi, Carol A., Jackson, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019349	A1	20020214
APPLICATION INFO.:	US 2001-780752	A1	20010209 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-181408P	20000209 (60)
	US 2000-200284P	20000428 (60)
	US 2000-242216P	20001020 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Paula A. Borden, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA, 94025	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	2559	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods of treating diseases related to **vasodilation**, generally comprising administering to an individual an effective amount of a pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 32 USPATFULL
ACCESSION NUMBER: 2002:227663 USPATFULL
TITLE: Uses for medical devices having a lubricious, nitric oxide-releasing coating
INVENTOR(S): Tedeschi, Eugene, Santa Rosa, CA, UNITED STATES
Shah, Chirag B., North Attleboro, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122814	A1	20020905
APPLICATION INFO.:	US 2002-137236	A1	20020430 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-726856, filed on 30 Nov 2000, GRANTED, Pat. No. US 6379691 Continuation-in-part of Ser. No. US 1999-405024, filed on 27 Sep 1999, GRANTED, Pat. No. US 6218016 Continuation-in-part of Ser. No. US 1998-163038, filed on 29 Sep 1998, GRANTED, Pat. No. US 6299980		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Christine Aceves, Medtronic AVE, 3576 Unocal Place, Santa Rosa, CA, 95403		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1241		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a

polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
ACCESSION NUMBER: 2001:597816 CAPLUS
DOCUMENT NUMBER: 135:175377
TITLE: Use of relaxin to treat diseases related to vasoconstriction
INVENTOR(S): Conrad, Kirk P.; Lewis, Martyn; Unemori, Elaine N.; Huang, Xinfan; Tozzi, Carol A.
PATENT ASSIGNEE(S): Connetics Corp., USA; The University of Pittsburgh - of the Commonwealth System of Higher Education; The University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058468	A1	20010816	WO 2001-US4370	20010209
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002019349	A1	20020214	US 2001-780752	20010209
EP 1253929	A1	20021106	EP 2001-909098	20010209
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-181408P	P 20000209
			US 2000-200284P	P 20000428
			US 2000-242216P	P 20001020
			WO 2001-US4370	W 20010209

AB The invention relates to methods of treating diseases related to vasoconstriction, generally comprising administering to an individual an effective amt. of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 32 USPATFULL DUPLICATE 4
ACCESSION NUMBER: 1999:110286 USPATFULL
TITLE: Method of using relaxin as therapeutic or preventing agent
INVENTOR(S): Bigazzi, Mario, Via del Palmerino No.11, Florence, Italy 50137

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 5952296		19990914
	WO 9503822		19950209
APPLICATION INFO.:	US 1995-403878		19950323 (8)
	WO 1994-IT124		19940726

19950323 PCT 371 date
19950323 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1993-FI143	19930727
	IT 1994-FI36	19940219
	IT 1994-FI39	19940225
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Delacroix-Muirheid, C.	
LEGAL REPRESENTATIVE:	McGlew and Tuttle, P.C.	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	750	
AB	Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis , hypertension and pregnancy's gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.	

L9 ANSWER 6 OF 32 USPATFULL

ACCESSION NUMBER: 1999:132779 USPATFULL
TITLE: Peptides having potassium channel opener activity
INVENTOR(S): Sinackevich, Nickolai V., St. Petersburg, Russian Federation
Rakhilov, Alexi M., St. Petersburg, Russian Federation
Maslennikov, Sergei V., St. Petersburg, Russian Federation
Green, Lawrence R., Tacoma, WA, United States
Cytran, Inc., Kirkland, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5972894		19991026
APPLICATION INFO.:	US 1997-908328		19970807 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Townsend & Townsend and Crew LLP		
NUMBER OF CLAIMS:	67		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3605		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns methods for prophylactic and therapeutic treatment of diseases responsive to the opening of potassium channels, peptides having potassium channel opener activities, and pharmaceutical compositions and kits comprising such peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14414 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14414 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human GAPDH.

L9 ANSWER 8 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14413 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14413 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is

therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human GAPDH.

L9 ANSWER 9 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14412 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14412 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human GAPDH.

L9 ANSWER 10 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14411 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation

and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14411 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) -PCR primer used to amplify human HGF.

L9 ANSWER 11 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14410 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14410 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic

wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human HGF.

L9 ANSWER 12 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14409 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYP1-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14409 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human bFGF.

L9 ANSWER 13 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14408 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYP1-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14408 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and **angiogenesis** in males as well as females and is therefore useful in treating a wide variety of diseases relating to **vasoconstriction**. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to **vasoconstriction** such as angiotensin-II-mediated **vasoconstriction**, endothelin-mediated **vasoconstriction** and for increasing **angiogenesis** and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human bFGF.

L9 ANSWER 14 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14407 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYP1-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14407 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and **angiogenesis** in males as well as females and is therefore useful in treating a wide variety of diseases relating to **vasoconstriction**. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**

, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription) -PCR analysis of human bFGF.

L9 ANSWER 15 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14406 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816

73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14406 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription) -PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 121.

L9 ANSWER 16 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14405 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14405 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 121.

L9. ANSWER 17 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14404 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYP1-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14404 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing

endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 121.

L9 ANSWER 18 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14403 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYP1-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14403 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 165.

L9 ANSWER 19 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14402 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYP1-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14402 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify human vascular endothelial cell growth factor (VEGF) 165.

L9 ANSWER 20 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14401 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816

73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14401 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated

vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of human rat vascular endothelial cell growth factor (VEGF) 165.

L9 ANSWER 21 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14400 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14400 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat GAPDH.

L9 ANSWER 22 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14399 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14399 DNA DGENE
AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat GAPDH.

L9 ANSWER 23 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14398 DNA DGENE
TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14398 DNA DGENE
AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The

gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat GAPDH.

L9 ANSWER 24 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14397 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14397 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L9 ANSWER 25 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14396 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14396 DNA DGENE
AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat bFGF.

L9 ANSWER 26 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14395 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYP1-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14395 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat bFGF.

L9 ANSWER 27 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14394 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14394 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 120.

L9 ANSWER 28 OF 32 DGENE (C) 2002 THOMSON DERWENT
ACCESSION NUMBER: AAD14393 DNA DGENE
TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -
INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.
(UYPI-N) UNIV PITTSBURGH.
(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PATENT INFO: WO 2001058468 A1 20010816 73p
APPLICATION INFO: WO 2001-US4370 20010209
PRIORITY INFO: US 2000-181408 20000209
US 2000-200284 20000428
US 2000-242216 20001020
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2001-514619 [56]
AN AAD14393 DNA DGENE
AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active

relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 120.

L9 ANSWER 29 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14392 DNA DGENE

TITLE: Treating pulmonary or renal hypertension and an ischemic condition, increasing vasodilation and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering relaxin -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816

73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14392 DNA DGENE

AB The invention relates to methods of treating diseases related to vasodilation by administering pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary hypertension, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing vasodilation, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. Relaxin is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal vasodilation and hyperfiltration. The gene encoding relaxin is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 120.

L9 ANSWER 30 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14391 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14391 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is an alpha sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L9 ANSWER 31 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14390 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A

PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816 73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14390 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to

vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense RT (reverse transcription)-PCR primer used to amplify rat vascular endothelial cell growth factor (VEGF) 164.

L9 ANSWER 32 OF 32 DGENE (C) 2002 THOMSON DERWENT

ACCESSION NUMBER: AAD14389 DNA DGENE

TITLE: Treating pulmonary or renal **hypertension** and an **ischemic** condition, increasing **vasodilation** and renal function, promoting wound healing and increasing production of angiogenic cytokine, comprises administering **relaxin** -

INVENTOR: Conrad K P; Lewis M; Unemori E N; Huang X; Tozzi C A
PATENT ASSIGNEE: (CONN-N) CONNETICS CORP.

(UYPI-N) UNIV PITTSBURGH.

(UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.

PATENT INFO: WO 2001058468 A1 20010816

73p

APPLICATION INFO: WO 2001-US4370 20010209

PRIORITY INFO: US 2000-181408 20000209

US 2000-200284 20000428

US 2000-242216 20001020

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2001-514619 [56]

AN AAD14389 DNA DGENE

AB The invention relates to methods of treating diseases related to **vasodilation** by administering pharmaceutically active **relaxin**. **Relaxin** functions to increase both **vasodilation** and angiogenesis in males as well as females and is therefore useful in treating a wide variety of diseases relating to vasoconstriction. The method is used for treating renal or pulmonary **hypertension**, treating ischaemic conditions such as ischaemic wound, stroke or ischaemic cardiac conditional, for increasing production of an angiogenic cytokine such as basic fibroblast growth factor (bFGF) or a vascular endothelial growth factor, increasing **vasodilation**, increasing renal function by increasing glomerular filtration rate, promoting wound healing, increasing nitric oxide production in an endothelial cell of a blood vessel endothelium and for increasing endothelin type B receptor activation in an endothelial cell in a blood vessel endothelium. **Relaxin** is useful for treating diseases related to vasoconstriction such as angiotensin-II-mediated vasoconstriction, endothelin-mediated vasoconstriction and for increasing angiogenesis and to promote neovascularisation in both males and females. It also promotes renal **vasodilation** and hyperfiltration. The gene encoding **relaxin** is used in gene therapy. The present sequence is a sense probe used in the RT (reverse transcription)-PCR analysis of rat vascular endothelial cell growth factor (VEGF) 164.

=>